Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Effective November 9, 2022 at 4:01 p.m. Eastern Time, Ampio Pharmaceuticals, Inc. (the "Company") amended its certificate of incorporation to implement a 15-to-1 reverse stock split.

As a result of the reverse stock split, at 4:01 p.m. Eastern Time on November 9, 2022, every 15 shares of common stock then issued and outstanding automatically were combined into one share of common stock, with no change in the $0.0001 par value per share. No fractional shares will be outstanding following the reverse stock split. Holders of fractional shares will be entitled to receive, in lieu of any fractional share, the number of shares rounded up to the next whole number. Immediately prior to the reverse stock split, the Company had 226,286,867 shares of common stock outstanding, which will be proportionately reduced for the 15-to-1 reverse stock split.

The text of the certificate of amendment is attached hereto as Exhibit 3.1 and incorporated herein by reference.

The reverse stock split will not change the number of authorized shares or the par value of the Company's common stock under the certificate of incorporation, which will continue to consist of 310,000,000 shares authorized, of which 10,000,000 shares, par value of $0.0001 per share, are designated as preferred stock and 300,000,000 shares, par value of $0.0001 per share, are designated as common stock.

The Company's common stock will begin trading on a post-split basis when the market opens on November 10, 2022.

The CUSIP identifier for the Company's common stock following the reverse stock split is 03209T 208.

Item 7.01. Regulation FD Disclosure.

On November 8, 2022, the Company issued a press release announcing the reverse stock split, the text of which is furnished as Exhibit 99.1 attached hereto.

Item 9.01. Financial Statements and Exhibits.




Exhibit No.     Description
3.1               Certificate of Amendment to Certificate of Incorporation of Ampio
                Pharmaceuticals, Inc. (effective as of November 9, 2022)
99.1              Press Release of Ampio Pharmaceuticals, Inc. dated November 8,
                2022
104             Cover Page Interactive Data File (embedded within the Inline XBRL
                document)

© Edgar Online, source Glimpses